Skip to main content
. 2018 Apr 20;9(30):21495–21511. doi: 10.18632/oncotarget.25138

Figure 4.

Figure 4

Therapeutic response of Ln229 cells stably expressing split-Renilla luciferase complementation sensor with different p53 variants (p53wt, p53Y220C, p53G245S, p53R282W) in response to the treatment of (A) Doxorubicin (1 μM), (B) Temozolomide (250 μM), (C) PhiKan083 (125 μM) and (D) SCH529074 (2.5 μM), for the change in cell viability and induced apoptosis.